Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MME | P08473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12352667 | 0.95 | LMNA (0.58) | MAPTLMNAMAPK1MMEALDH1A1 | |
| SCHEMBL22294656 | 0.95 | LMNA (0.58) | MAPTLMNAMAPK1MMEALDH1A1 | |
| SCHEMBL19152432 | 0.90 | MAPT (0.72) | MAPTLMNAMAPK1MMEALDH1A1 | |
| SCHEMBL8826260 | 0.88 | MME (0.58) | MAPTLMNAMAPK1MMEALDH1A1 | |
| SCHEMBL8826267 | 0.88 | MME (0.58) | MAPTLMNAMAPK1MMEALDH1A1 | |
| SCHEMBL10707753 | 0.84 | MMP8 (0.56) | KMT2AEPHX2POLBCNR2CTSK | |
| SCHEMBL10283303 | 0.83 | MME (0.65) | MAPTLMNAMAPK1MMEALDH1A1 | |
| SCHEMBL10031574 | 0.83 | MME (0.65) | MAPTLMNAMAPK1MMEALDH1A1 | |
| SCHEMBL1516159 | 0.83 | MME (0.65) | MAPTLMNAMAPK1MMEALDH1A1 | |
| SCHEMBL7272130 | 0.83 | SPHK1 (0.61) | KMT2AEPHX2L3MBTL1POLBCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969333-B2 | Therapeutic compositions and methods | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140288059-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-09-25 | — | — | US | disclosed |
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288059-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PADI4, PADI2, PADI3 | MAPT 4434/4885LMNA 2958/4885MAPK1 4201/4885 |
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PADI4, PADI2, PADI3 | MAPT 4434/4885LMNA 2958/4885MAPK1 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.